Physician profile
Ivan C Ashton
NPI 1497804678
$1,119.68
in general payments reported to CMS, 2019-2025
11 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $176 · 2021: $102 · 2022: $161 · 2023: $253 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $372 · Food and Beverage: $34.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $372.00 |
| Food and Beverage | $34.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $372.00 | 2023-2025 | Dr Comfort |
| Sandoz INC. | $180.73 | 2019-2020 | |
| Sebela Pharmaceuticals INC. | $157.71 | 2019-2022 | |
| Orthofix Medical, INC. | $123.48 | 2022 | |
| Horizon Therapeutics Plc | $111.42 | 2020-2021 | |
| Journey Medical Corporation | $62.99 | 2020-2023 | |
| Hikma Pharmaceuticals USA | $30.37 | 2019-2023 | Mitigare |
| Integra Lifesciences Corporation | $24.92 | 2019 | |
| Alfasigma USA, INC. | $19.79 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.97 | 2020 | |
| Forte Bio-Pharma LLC | $17.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Ashton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.